Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB.

[1]  R. Zhong,et al.  Monoclonal antibody against CD45RB for the therapy of rejection and autoimmune diseases , 1998, Journal of Molecular Medicine.

[2]  A. Diepstra,et al.  Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Linsley,et al.  IFN-gamma is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways. , 1998, Journal of immunology.

[4]  J. Soulillou,et al.  Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients , 1997, The Lancet.

[5]  K. Wood,et al.  The induction of operational tolerance is not prevented by simultaneous administration of cyclosporin A1 , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  D. Rothstein,et al.  Indefinite islet allograft survival in mice after a short course of treatment with anti-CD45 monoclonal antibodies. , 1997, Transplantation.

[7]  J. Wang,et al.  Prevention of heart allograft and kidney xenograft rejection by monoclonal antibody to CD45RB. , 1997, Transplantation proceedings.

[8]  Fadi G Lakkis,et al.  Acute rejection of vascularized heart allografts in the absence of IFNgamma. , 1996, Transplantation.

[9]  I. Autenrieth,et al.  Interleukin-2 is indispensable for development of immunological self-tolerance. , 1996, Clinical immunology and immunopathology.

[10]  V. Holan,et al.  Production of high levels of Th1 and Th2 cytokines in mice with acquired transplantation tolerance. , 1996, Cellular immunology.

[11]  C. Stiller,et al.  Pattern of liver, kidney, heart, and intestine allograft rejection in different mouse strain combinations. , 1996, Transplantation.

[12]  R. Germain,et al.  Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Halloran,et al.  Quantitating immunosuppression. Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice. , 1996, Transplantation.

[14]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[15]  S. Poppema,et al.  Prevention and reversal of renal allograft rejection by antibody against CD45RB , 1996, Nature.

[16]  G. Opelz.  EFFICACY OF REJECTION PROPHYLAXIS WITH OKT3 IN RENAL TRANSPLANTATION , 1995, Transplantation.

[17]  P. Nickerson,et al.  IL-2 knockout recipient mice reject islet cell allografts. , 1995, Journal of immunology.

[18]  P. Fields,et al.  Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A , 1995, European journal of immunology.

[19]  B. Reitz,et al.  In vivo studies of the maintenance of peripheral transplant tolerance after cyclosporine. Radiosensitive antigen-specific suppressor cells mediate lasting graft protection against primed effector cells. , 1995, Transplantation.

[20]  B D Kahan,et al.  The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice , 1995, Transplantation.

[21]  M. Crumpton,et al.  CD7 is associated with CD3 and CD45 on human T cells. , 1994, Journal of immunology.

[22]  P. Linsley,et al.  The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival. , 1994, The Journal of surgical research.

[23]  T. Chou,et al.  Synergistic immunosuppressive actions of cyclosporine with a mouse anti+-rat α/β-T cell receptor monoclonal antibody , 1994 .

[24]  P. Fields,et al.  Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  G. Prud’homme,et al.  Cyclosporine, tolerance, and autoimmunity. , 1993, Clinical immunology and immunopathology.

[26]  Shu-chen Wu,et al.  A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATION , 1993, Transplantation.

[27]  R. Schwartz.  Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy , 1992, Cell.

[28]  S. Poppema,et al.  INHIBITION OF ALLOREACTIVITY IN VITRO BY MONOCLONAL ANTIBODIES DIRECTED AGAINST RESTRICTED ISOFORMS OF THE LEUKOCYTE‐COMMON ANTIGEN (CD45) , 1992, Transplantation.

[29]  C. Morimoto,et al.  Cyclic regulation of CD45 isoform expression in a long term human CD4+CD45RA+ T cell line. , 1991, Journal of immunology.

[30]  D. Mason,et al.  Memory CD4+ T cells in man form two distinct subpopulations, defined by their expression of isoforms of the leucocyte common antigen, CD45. , 1990, Immunology.

[31]  R. Gorczynski,et al.  Cyclosporin alters the induction of allospecific tolerance in vivo. , 1987, Immunology letters.

[32]  T. Strom,et al.  Sparing of suppressor cells: a critical action of cyclosporine. , 1984, Transplantation.

[33]  E. Reinherz,et al.  Treatment of acute renal allograft rejection with monoclonal anti-T12 antibody. , 1983, Transplantation.

[34]  G. Goldstein,et al.  EFFECTS OF IN VIVO ADMINISTRATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR HUMAN T CELL SUBPOPULATIONS ON THE IMMUNE SYSTEM IN A RHESUS MONKEY MODEL , 1983, Transplantation.

[35]  J. Fabre,et al.  Immunosuppressive properties of rabbit antibodies against a major glycoprotein restricted to rat leukocyte membranes. , 1980, Transplantation.

[36]  J. Fabre,et al.  QUANTITATIVE SEROLOGICAL ANALYSIS OF A RABBIT ANTI‐RAT LYMPHOCYTE SERUM AND PRELIMINARY BIOCHEMICAL CHARACTERISATION OF THE MAJOR ANTIGEN RECOGNISED , 1977, Transplantation.

[37]  J. Marchalonis,et al.  Glycoproteins of murine thymocyte and splenocyte surface membranes; binding to concanavalin A and recognition by heterologous antilymphocyte serum. , 1976, Immunochemistry.

[38]  I. Trowbridge,et al.  CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. , 1994, Annual review of immunology.

[39]  T. Mustelin,et al.  Molecular events mediating T cell activation. , 1990, Advances in immunology.

[40]  R. Calne.  Immunological Aspects of Transplantation Surgery , 1973, Springer Netherlands.

[41]  R. Corry,et al.  New Possibilities for Organ Allografting in the Mouse , 1973 .